assessing real-world outcomes with new hcv regimens in...

CME-certifi ed Dinner Symposium

Course Chair

David R. Nelson, MDFaculty

Ira M. Jacobson, MDNancy Reau, MDMark Sulkowski, MD

MONDAY, NOVEMBER 10, 2014Sheraton Boston HotelGrand/Independence Ballroom (Level 2) ★ Boston, MA

This continuing medical education activity is provided by

Educational Partner

We gratefully acknowledge the following company for their educational grant in

support of this educational activity. Janssen Therapeutics,

Division of Janssen Products, LP

Presented for attendees of the 65th AASLD Annual Meeting (or The Liver Meeting®)

This is not an offi cial event of the American Association for the Study of Liver Diseases.

VINDICOmedical education

6:00 pm – 6:30 pm Registration & Dinner

6:30 pm – 8:15 pm CME-certifi ed ProgramREGISTER TODAY!

VindicoCME.com/111014

HCV-TARGET REGISTRY FINDINGS

Assessing Real-World Outcomes with New HCV Regimens in 2014

1.75

REGISTER TODAY!

We gratefcompany

C

MSG

6R

6C

REGISTER TODAY!VindicoCME.com/111014

OverviewThe fi eld of HCV treatment is rapidly evolving, with 2 new direct-acting antiviral agents (DAA) approved at the end of 2013 and several more in the pipeline. HCV-TARGET is an interna-tional consortium of academic and community investigators prospectively enrolling patients treated with HCV regimens that include a DAA to assess the effects of HCV therapy in the broader population. The HCV-TARGET initiative aims to continue to evaluate the safety and ef-fi cacy of HCV regimens, including a robust data set of traditionally underrepresented patient populations, such as those with cirrhosis, null responders, older adults, African Americans, Hispanics, and patients infected with mutated strains of HCV. This CME activity will consider real-world data of patients treated with new regimens to provide an understanding of how and when specifi c regimens are most benefi cial, particularly in challenging patients with HCV genotype 1, and will review the current HCV practice guidelines and how and when to use the new treatment regimens.

Learning ObjectivesUpon successful completion of this activity, participants will be able to:

• Evaluate the 2014 recommendations of the AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C and determine how they may be used in real-world applications.

• Evaluate real-world data, in addition to clinical trial data, for the treatment of challenging patients with genotype 1 HCV.

• Assess the success of treatment strategies that have incorporated the use of newly approved second-generation DAA regimens in challenging patients with genotype 1 HCV.

• Evaluate the effi cacy, safety, and cost-effectiveness of the fi rst available second-generation DAA regimens in clinical trials and in real-life scenarios in order to more effectively com-municate the risk-benefi t ratio to patients, as well as choose the most appropriate therapy for individual patients with HCV.

Target Audience The intended audience for this activity is hepatologists, gastroenterologists, infectious disease specialists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with HCV.

© 2014 Vallancien/Phototake, Inc. V14-0637© 20© 2014 V14 Vallaallanciencien/Phn/Phototototakeake, IncInc. V14-V14 06370637

OThwapintiointretobraifi cseporeHstrereanpageprth


Agenda6:30 pm – 6:40 pm Introduction and Pretest

David R. Nelson, MD

6:40 pm – 7:05 pm HCV-TARGET – Real-World Data Promising Real-World SolutionsMark Sulkowski, MD

7:05 pm – 7:25 pm Real-World Outcomes: Special Populations and Management IssuesNancy Reau, MD

7:25 pm – 7:45 pm Treating Amid New Guidelines and Options – How to Decipher and Apply to PracticeIra M. Jacobson, MD

7:45 pm – 8:00 pm Applying What We’ve Learned and Identifying What Gaps Remain – A Panel DiscussionAll Faculty; David R. Nelson, MD, Moderator

8:00 pm – 8:05 pm PosttestDavid R. Nelson, MD

8:05 pm – 8:15 pm Question and AnswerDavid R. Nelson, MD

NOT GOING TO BOSTON?

Get notified when online activity goes live.www.surveymonkey.com/s/KXS3RTM

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant fi nancial relationships. Relevant fi nancial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

Gw

Th1.7co

In Stain prowi

FacAupro

Course Chair Faculty

David R. Nelson, MDProfessor Assistant Vice President for ResearchUniversity of FloridaGainesville, FL

Ira M. Jacobson, MDVincent Astor Professor of MedicineWeill Cornell Medical CollegeChief, Division of Gastroenterology and HepatologyNew York, NY

Nancy Reau, MDAssociate Professor of MedicineUniversity of Chicago School of MedicineChicago, IL

Mark Sulkowski, MDProfessor of MedicineJohns Hopkins UniversityBaltimore, MD


CC F

Priority Code: 579 - 1 2 3

Contact Information:E-mail: [email protected]

Toll-free: 877-307-5225, ext. 219 or 476

Phone: 856-994-9400, ext. 219 or 476

Fax: 856-251-0278

Mail: Registration Department 6900 Grove Road Thorofare, NJ 08086-9447

REGISTER TODAY!VindicoCME.com/111014Preregistration is encouraged but not required. Seating to be based on arrival order; early arrival is recommended.

ADA compliance: In compliance with the Americans with Disabilities Act of 1990, we will make reasonable efforts to accommodate persons with disabilities. Please call with your requests.

First Name ______________________________ M.I._______ Last Name _________________________________________

Preferred Mailing Address (Home/Business) ___________________________________________________________________

______________________________________________________________________________________________________

City ___________________________ State_______ Zip Code ______________ Country ____________________________

Daytime Phone _______________________________________ Evening Phone ______________________________________

Fax ____________________________ E-mail ______________________________________ Date of Birth _______________

National Provider Identifier (NPI)_______________ Medical License Number______________ Medical License State____________

(for confirmation purposes) (for confirmation purposes) (for tracking credits ONLY)

How did you hear about this meeting?(multiple selections allowed)❑ Advertisement ❑ Brochure

❑ E-mail❑ Postcard

❑ Web site❑ Word of mouth

Specialty (select one)❑ Gastroenterology❑ Hepatology❑ Infectious Disease

Degree (please specify)❑ MD/DO❑ PhD❑ MD, PhD

❑ Internal Medicine❑ Family Practice/General Practice❑ Other:______________

❑ PharmD/RPh❑ PA❑ RN/BSN/MSN

❑ NP❑ Industry❑ Other:_______

CME Activity Request❑ YES, I would like to receive information regarding future

CME activities related to this therapeutic area.




1.75MONDAY, NOVEMBER 10, 2014Sheraton Boston HotelGrand/Independence Ballroom (Level 2)Boston, MA

6:00 pm – 6:30 pmRegistration & Dinner

6:30 pm – 8:15 pmCME-certifi ed Program

4

6900 Grove Road • Building 100Thorofare, NJ 08086-9447

VINDICOmedical education

PresortedFirst Class Mail

US PostagePAID

Permit # 906Bellmawr NJ


MONDAY NOVEMBER 10, 2014Sheraton Boston HotelGrand/Independence Ballroom (Level 2)Boston, MA

6:00 pm – 6:30 pmRegistration & Dinner

6:30 pm – 8:15 pmCME-certifi ed Program




1.75

MSGB

6R

6C

C

H

Aw

assessing real-world outcomes with new hcv regimens in...

Documents